Dean Hickman, MD
Psychiatry · New Orleans, LANPI 1093763336
Payments from drug & device makers
Across 114 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$889
- Johnson & Johnson$632
- Neurocrine Biosciences, Inc.$472
- Indivior Inc.$435
- Lundbeck LLC$160
- Otsuka America Pharmaceutical, Inc.$86
- plus $222 from 6 others
What the payments were for
- Food & beverage$2,86999%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 35 | $889 |
| Johnson & Johnson | 16 | $632 |
| Neurocrine Biosciences, Inc. | 21 | $472 |
| Indivior Inc. | 17 | $435 |
| Lundbeck LLC | 10 | $160 |
| Otsuka America Pharmaceutical, Inc. | 5 | $86 |
| Teva Pharmaceuticals USA, Inc. | 3 | $76 |
| AbbVie | 2 | $54 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Bioxcel Therapeutics, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,897 in reported general payments places this provider in the 80th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 39 | $7,805 |
| Bupropion XlBupropion Hcl | 78 | $2,310 |
| Duloxetine Hcl | 45 | $1,091 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $726 |
| Methylphenidate Hcl | 13 | $725 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 47 | $689 |
| Escitalopram Oxalate | 39 | $661 |
| Mirtazapine | 41 | $614 |
| Clonazepam | 41 | $578 |
| Bupropion Hcl SrBupropion Hcl | 13 | $535 |
| Gabapentin | 31 | $509 |
| Olanzapine | 21 | $499 |
| Aripiprazole | 13 | $273 |
| Buspirone Hcl | 16 | $270 |
| Quetiapine Fumarate | 25 | $269 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New Orleans
- Arwen PodestaNew Orleans$466K
- Andrew MorsonNew Orleans$56K
- James BarbeeNew Orleans$28K
- Neha KansaraNew Orleans$13K
- Erich ConradNew Orleans$9K
- Rahn BaileyNew Orleans$8K
- Nick RamandiNew Orleans$8K
- Ashley WeissNew Orleans$8K
- Ravindra ReddyNew Orleans$7K
- Paul PeltsNew Orleans$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.